Considerations for an In Vitro , Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms

Drug-induced effects on cardiac contractility can be assessed through the measurement of the maximal rate of pressure increase in the left ventricle (LVdP/dt ) in conscious animals, and such studies are often conducted at the late stage of preclinical drug development. Detection of such effects earl...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2019-08, Vol.10, p.884-884
Main Authors: Guth, Brian D, Engwall, Michael, Eldridge, Sandy, Foley, C Michael, Guo, Liang, Gintant, Gary, Koerner, John, Parish, Stanley T, Pierson, Jennifer B, Ribeiro, Alexandre J S, Zabka, Tanja, Chaudhary, Khuram W, Kanda, Yasunari, Berridge, Brian
Format: Article
Language:English
Subjects:
cardiomyocyte
contractility
inotropic state
myocardium
Pharmacology
stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug-induced effects on cardiac contractility can be assessed through the measurement of the maximal rate of pressure increase in the left ventricle (LVdP/dt ) in conscious animals, and such studies are often conducted at the late stage of preclinical drug development. Detection of such effects earlier in drug research using simpler, test systems would be a valuable addition to our strategies for identifying the best possible drug development candidates. Thus, testing platforms with reasonably high throughput, and affordable costs would be helpful for early screening purposes. There may also be utility for testing platforms that provide mechanistic information about how a given drug affects cardiac contractility. Finally, there could be testing platforms that could ultimately contribute to the regulatory safety package of a new drug. The characteristics needed for a successful cell or tissue-based testing platform for cardiac contractility will be dictated by its intended use. In this article, general considerations are presented with the intent of guiding the development of new testing platforms that will find utility in drug research and development. In the following article (part 2), specific aspects of using human-induced stem cell-derived cardiomyocytes for this purpose are addressed.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2019.00884